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INTRODUCTION
Cholesterol crystal embolism is a multisystemic dis-
order characterized by the occlusion of small arteries by
cholesterol crystal emboli deriving from eroded athero-
sclerotic plaques of the aorta (1-7). The proximity of the
kidneys to the abdominal aorta makes the kidney the
most frequent target organ. In the past, cholesterol
crystal embolization has been frequently overlooked as
a cause of renal dysfunction. Usually, the diagnosis was
made post-mortem (1-3). We discuss the pathogenesis,
incidence and clinico-pathological findings of athero-
embolic renal disease.
PATHOGENESIS
The formation of a complicated  atherosclerosis le-
sion is a prerequisite for the development of cholesterol
crystal emboli syndrome. Plaques with a large extracel-
lular lipid-rich core and thin fibrous cap appear to be
most vulnerable to rupture. Mechanical and hemody-
namic stresses can rupture the fibrous cap, releasing
the underlying extracellular cholesterol-rich matrix.
Atheroembolization can occur spontaneously or after
aortic wall trauma, including vascular surgery and an-
giographic procedures. Another etiologic factor is anti-
coagulation. Vascular surgery can disrupt plaques dur-
Heart International / Vol. 2 no. 3-4, 2006 / pp. 155-160 © Wichtig Editore, 2007
Cholesterol crystal embolism (atheroembolism)
CHIARA VENTURELLI, GUIDO JEANNIN, LAURA SOTTINI, NADIA DALLERA, FRANCESCO SCOLARI
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bolization can occur spontaneously or as an iatrogenic complication from an invasive vascular
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bolism can give rise to different degrees of renal impairment. Some patients show a moderate
loss of renal function, others severe renal failure requiring dialysis. Renal outcome can be vari-
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chronic renal impairment. Clinically, three types of atheroembolic renal disease have been de-
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vous system. The diagnosis is difficult and controversial for the protean extrarenal manifesta-
tions. In the past, the diagnosis was often made post-mortem. In the last 10 yrs, awareness of
atheroembolic renal disease has improved. The correct diagnosis requires the clinician to be
alert. The typical patient is a white male aged >60 yrs with a history of hypertension, smoking and
arterial disease. The presence of a classic triad (precipitating event, renal failure and peripheral
cholesterol crystal embolization) suggests the diagnosis. This can be confirmed by a biopsy of
the target organs. A specific treatment is lacking; however, it is an important diagnosis to make
because an aggressive therapeutic approach can be associated with a more favorable clinical
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ing incisions, clamping or manipulation of the vessels.
Radiological aortic instrumentation can act by inducing
a mechanical trauma: catheter manipulations scrape
the walls of the aorta, disrupting the atherosclerotic
plaques. The third precipitating factor described is anti-
coagulant treatment, including both heparin and oral
anticoagulants. These agents can prevent the formation
of a protective thrombus overlying an ulcerated plaque
or could initiate the disruption of a complex plaque by
causing a hemorrhage into it. Thrombolytic therapy may
lyze thrombi, including those covering atherosclerotic
plaques (8-11). Once in the circulation, cholesterol crys-
tal emboli lodge in small arteries, 150-200 mm in diam-
eter; this is followed by an inflammatory reaction, inti-
mal proliferation and intravascular fibrosis. The entire
process results in the narrowing or obliteration of the lu-
men, causing ischemic changes (7). 
EPIDEMIOLOGY
The syndrome of renal cholesterol crystal embolism
usually affects elderly males with a history of diffuse
atherosclerosis (1-3). The true incidence of atheroem-
bolic renal disease is difficult to estimate. Retrospective
autopsy (incidence 10-27%) or biopsy (incidence 1%)
studies can exaggerate the frequency of the disease be-
cause they could detect subclinical cases. Conversely,
the incidence of atheroembolic renal disease in clinical
studies appears to be much less than that observed in
autopsy and biopsy studies. However, in these studies,
clinically significant atheroembolism has probably been
underestimated due to short-term follow-up. Estimates
of atheroembolic renal disease incidence after aortic
catheterization is <0.2%, appearing to be much less
than those observed in autopsy and biopsy studies (5,
8, 10-12). However, it remains difficult to quantify the
magnitude of clinically significant angiography-associ-
ated atheroembolism because the majority of studies
did not search the disease systematically, which can
manifest weeks to months after the procedure.
PATHOLOGICAL CHARACTERISTICS
The histological features of renal cholesterol crystal
embolization are highly characteristic (1-3). The hall-
mark of the condition is an occlusion of the lumen of the
small arteries by atherosclerotic material. As the lipids
are dissolved by the techniques used to prepare the tis-
sue for histological examination, the cholesterol crys-
tals may be identified by the presence of needle-shaped
spaces, which appear empty in routine histological sec-
tions. Therefore, clefts are found that remain after cho-
lesterol has dissolved during fixation. Renal histological
examination shows characteristic, biconvex, needle-
shaped clefts in vessels between 50-200 mm in diame-
ter (arcuate and interlobular arteries). Rarely, the cho-
lesterol crystals lodge in the afferent arteries and
glomeruli. Numerous foci of patchy, irregular atrophy of
the renal parenchyma and occasional areas of ischemic
infarction can be seen. In the involved areas, glomeruli
show various degrees of obsolescence or ischemic re-
traction of the tuft. Many tubules show atrophic
changes from slight to severe; areas of acute tubular
necrosis may also be present (1-3). 
CLINICAL FEATURES
The clinical consequences of cholesterol crystal em-
bolization vary considerably. Patients can be complete-
ly asymptomatic when the diagnosis is made coinciden-
tally at renal biopsy, or they can present with a distinct
clinical syndrome, ranging from a cyanotic toe to a mul-
tiorgan systemic disease that can mimic other systemic
diseases (1-6, 8-11). The distribution of end-organ dam-
age depends on the anatomic location of the original
atherosclerotic plaques and the extent of organ involve-
ment. For instance, cholesterol crystal embolization
from carotid artery plaques leads to clinical involvement
confined to the retinal and cerebral circulation. Howev-
er, when the source of the atheroemboli is in the tho-
racic aorta or, more commonly, the abdominal aorta, the
central nervous system, visceral organs, and extremi-
ties can be involved. Only the lower extremities are in-
volved if the site is below the renal arteries. Moreover,
individuals at risk of renal cholesterol crystal embolism
commonly have other chronic illnesses causing renal
failure, such as hypertension, renovascular disease and
diabetes mellitus. Finally, patients at risk of atheroem-
bolic renal disease usually have multiple risk factors for
atherosclerosis and almost always have symptomatic
atherosclerosis (1-6, 8-11). Venturelli et al
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Renal involvement
The kidney is the most frequent target organ for
cholesterol crystal embolization. Although a small
non-significant cholesterol crystal embolism can oc-
cur in the kidneys and be clinically silent, renal clinical
manifestations are found at presentation or during the
course of the clinical illness in approximately 50% of
patients (1-3). In patients with the disease occurring
after angiographic and vascular surgical procedures,
the interval from the inciting event to the onset of renal
symptoms can vary greatly. Some patients have imme-
diate clinical features, but in others, the onset can be
more insidious, with a delay of weeks or months be-
tween the precipitating event and clinical features 
(1-6, 8-11). Clinically, three types of atheroembolic re-
nal disease have been described. In the first type, re-
nal impairment can onset suddenly. This acute form of
renal failure develops a few days after the inciting
event and is considered to be due to a massive em-
bolization. The second type of atheroembolic renal
disease, the most frequently observed, is character-
ized by a subacute time course, probably explained by
the foreign-body reaction or the cyclic occurrence of
cholesterol crystal emboli showers. In this setting, re-
nal impairment occurs in a stepwise fashion. A third
clinical form has been observed which presents as
chronic and stable renal impairment associated with
the clinical presentation of nephroangiosclerosis
and/or ischemic nephropathy (10, 12). 
The renal outcome for patients with atheroembolic
renal disease can be variable; some patients deterio-
rate or remain on dialysis, some improve, and some
remain with chronic impairment. In both the acute and
subacute scenarios, dialysis could be required in 28-
61% of patients. In early reports, renal outcome was
described as quite dismal, with progression over
weeks to months to end-stage renal failure. However,
more recent experiences suggest less inexorable de-
terioration, with a possibility for the spontaneous re-
covery of renal function in approximately one-third of
patients, even after variable periods of dialytic sup-
port (8-10). Renal function recovery is probably
caused by several factors, such as reversal of inflam-
mation, resolution of acute tubular necrosis in is-
chemic areas and hypertrophy in surviving nephrons
(10, 12). 
Cutaneous manifestations
Among extrarenal findings, the most common is the
skin. Cutaneous features most often found are purple toes
and livedo reticularis. Typically, the purple/blue toe syn-
drome presents as the sudden appearance of a small,
cool, cyanotic and painful area of the foot (usually a toe).
The lesion is usually bilateral, and can progress to ulcera-
tion, digital infarcts and gangrene. In the majority of pa-
tients, the presence of digital cyanosis is characterized by
well-preserved peripheral pulses (1-6). Livedo reticularis
is also a frequent skin lesion. This consists of a blue-red
mottling of the skin in a netlike pattern, most likely caused
by the obstruction of small arteries, capillaries or venules
in the deep dermis. It is often seen on the feet, legs, but-
tocks and lumbar region (1-3). Other dermatologic mani-
festations include nodules, which appear as the result of
an inflammatory reaction surrounding cholesterol crys-
tals, purpura and petechiae.
Gastrointestinal involvement
Atheroemboli to the gastrointestinal tract represent
an important often unsuspected cause of abdominal
manifestations. Involvement of the digestive system
varies from 18.6-48% and can occur at any site along its
length, producing many, often misleading, presenta-
tions (1-3, 12). Usually, the prognosis of patients with
gastrointestinal disease is poor; the overall death rate is
high. The most common mode of presentation of cho-
lesterol crystal embolism to the bowel is hemorrhage
and abdominal pain. Gastrointestinal bleeding most of-
ten results from superficial mucosal ulcerations, ero-
sions or mucosal infarcts. Clinical presentation can
range from occult blood loss and melena to bloody diar-
rhea, depending on the site and the extent of the le-
sions. Abdominal pain can be caused by non-infarctive
ischemia, also inducing malabsorption and diarrhea, or
by fibrous stricture with bowel obstruction caused by
tissue-repair reactions after repeated showers of
atheroemboli. Pancreatitis is a rare presentation, al-
though the pancreas is a frequent emboli site. Necrotiz-
ing acalculous cholecystitis has been reported rarely.
Intestinal symptoms, consisting mostly of nausea, ab-
dominal pain, diarrhea and gastrointestinal bleeding,
were present in 10-33% of patients in the largest patient
series published (12). Cholesterol crystal embolism (atheroembolism)
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Central nervous system manifestations
Cerebral cholesterol crystal embolism can be associ-
ated with various symptoms, such as transient ischemic
attacks, cerebral infarction, amaurosis fugax, paralysis,
confusional states and gradual deterioration in neuro-
logical function. In the largest case series, neurological
manifestations occurred in 4-23% of patients with renal
cholesterol emboli syndrome (2, 3, 8, 9). In clinical stud-
ies, a definite diagnosis of atheroemboli in the brain is
difficult to make, and it ultimately depends on evidence
of cholesterol crystal emboli to other organs. Finally, the
retina is a frequent target organ, providing a unique op-
portunity to observe emboli. Although carotid artery dis-
ease may be more frequently the origin of retinal cho-
lesterol crystal emboli, when central nervous system
emboli accompany the more generalized form of the
disorder, cholesterol crystal emboli arise from the prox-
imal part of the aorta. The incidence of retinal choles-
terol crystal emboli, responsible for retinal ischemic
events, varies greatly, ranging from 6-25% in patients,
and depends on the proportion of patients in whom the
fundi were examined and the thoroughness of the ex-
amination (8, 9). 
Other extrarenal manifestations
Showers of cholesterol crystals can occur in virtual-
ly any organ. Myositis and splenic infarcts are rare
manifestations. Although uncommon, atheroemboli
can involve the coronary arteries; the usual source is
the aortic root or the proximal coronary artery. Recent-
ly, cholesterol crystal embolization to the lung has
been described, suggesting that atheroembolic renal
disease should be considered a new cause of pul-
monary-renal syndrome. Non-specific findings, such
as fever, weight loss, myalgias and headache, have
been reported in a minority of patients and could sug-
gest a systemic disease (1-3, 8-10).
LABORATORY FEATURES
Laboratory features are non-specific. However, var-
ious laboratory tests help establish the  cholesterol
crystal embolism diagnosis. Atheroembolic renal dis-
ease is first characterized by elevations in serum crea-
tinine (Cr) and blood urea nitrogen levels. Urinary in-
vestigation is generally non-diagnostic because it
shows such non-specific alterations as mild protein-
uria and microhematuria with hyaline and granular
casts. Hematuria is found in 33-40% of patients; pro-
teinuria in the non-nephrotic range can be detected in
50-60% of patients (2, 3, 8, 9). In our series, urinalysis
showed mild-moderate proteinuria in the majority of
patients (10, 12). Among the extrarenal laboratory fea-
tures, eosinophilia appears to be the most common
finding. An 80% incidence of eosinophilia was found
when adequate white blood cell counts and differen-
tials were reported. Subsequent reports found an inci-
dence of eosinophilia varying from 14-71% (3, 8, 9, 10,
12). Laboratory markers of acute inflammation, such
as erythrocyte sedimentation rate, serum C-reactive
protein level and fibrin level, could be increased in a
substantial proportion of cases (1-3). Hypercholes-
terolemia is a well-known risk factor for atherosclero-
sis of which crystal embolization can be considered a
direct complication. However, the most important
studies of atheroembolism usually have not reported
serum cholesterol levels. Recently, hypercholes-
terolemia was considered a substantive risk factor for
renal atheroembolization and it was found that 27% of
patients had hypercholesterolemia (2, 3, 8-11).
DIAGNOSIS
Diagnostically, cholesterol crystal embolism has
challenged physicians for over a century. This is
probably because atheroembolism is ubiquitous,
with random and variable distributions in the body.
Knowledge of the associated risk factors, recogni-
tion of its multiple clinical presentations, and its con-
sideration after certain vascular invasive procedures
could allow a pre-mortem diagnosis in a significant
number of cases. The typical patient is a white male
aged >60 yrs with a baseline history of hypertension,
smoking and arterial disease (1-6, 8-11). The pres-
ence of a triad composed of a precipitating event,
acute or subacute renal failure and peripheral cho-
lesterol crystal embolization strongly suggests the
diagnosis (9-11). The presence of other complica-
tions of atheroembolism, such as gastrointestinal
bleeding and neurological involvement, should raiseVenturelli et al
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the  suspicion level. Among the laboratory features,
helpful clues to the diagnosis include the presence of
eosinophilia and an increase in acute inflammation
markers. Histological confirmation has traditionally
been considered essential to the pre-mortem diag-
nosis of atheroembolic renal disease (1-6). The con-
firmatory diagnosis involves a biopsy of the target or-
gans. Renal biopsy should be considered the most
definitive method of diagnosing atheroembolic renal
disease (7). However, during the acute disease
phase, many patients can be too sick to proceed with
renal biopsy: in this setting, the use of an invasive
procedure may not be justified. Moreover, because
cholesterol crystal embolization is a patchy process,
a focal lesion can elude the histological examination.
Alternatively, the biopsy of characteristic cutaneous
lesions could yield a positive diagnosis in several
cases. Skin biopsy is a simple non-invasive proce-
dure that can be easily performed. The histological
confirmation of cutaneous atheroemboli was possi-
ble in 92% of patients (n=24) in whom a skin biopsy
specimen was obtained. Skin lesions represent an
easily accessible site. For this and for the frequency
of the peripheral ischemic changes, skin biopsy
specimens should be considered the best sample of
choice for histological diagnosis (10, 12). Regarding
the diagnosis, two final points deserve considera-
tion. First, in the appropriate clinical setting, oph-
thalmoscopic examination showing retinal choles-
terol crystal emboli could establish the diagnosis in a
significant number of patients. Secondly, in contrast
to the accepted teaching, in the presence of a spe-
cific set of clinical features (a triad including a pre-
cipitating event, subacute renal failure and peripher-
al cholesterol crystal embolization), the diagnosis of
atheroembolic renal disease can be made without
histological evaluation (9-11). 
The differential diagnosis first includes contrast
nephropathy, which immediately follows the radi-
ographic study. There is an increase in Cr level a few
days after the procedure; peak Cr level elevation oc-
curs approximately 1 week after exposure and re-
turns to baseline within 10-14 days (13). Conversely,
atheroembolic renal damage frequently has a de-
layed onset (days to weeks) and a protracted course;
the outcome is often poor, resulting in progressive
renal failure requiring dialysis.
MANAGEMENT AND OUTCOME
To date, no effective treatment is available for this
condition. Anticoagulants should be avoided because
they can potentiate the problem. Disagreement exists
concerning steroid treatment. Recently, statins have
been found to be associated with better renal outcome.
In the context of the emerging evidence of statin-in-
duced plaque stabilization and regression (14, 15), the
possible role of an aggressive lipid lowering therapy in
the conservative treatment of cholesterol crystal em-
bolization should be evaluated in a proper prospective
study. 
Medical treatment is mostly symptomatic, and sup-
portive measures, including dialysis, are appropriate.
Surgery is rarely indicated because the source of cho-
lesterol crystal embolization is frequently uncertain.
Moreover, patients are usually too weak for a major sur-
gical intervention and the necessary aortic clamping
during surgery would induce a major risk of recurrence.
Prevention is very important; the main recommendation
is to restrict the indications of angiography and surgical
procedures as much as possible in severely atheroscle-
rotic patients. 
Patients with atheroemboli have a dismal outlook.
Historically, the 1-yr mortality rate ranged from 64-87%
(2, 3, 6, 8). However, in two recent studies, an aggres-
sive supportive treatment was associated with a 1-yr
survival rate of 79 (9) and 69% (16), respectively. This
management was characterized by the avoidance of an-
ticoagulation, good control of hypertension and heart
failure, dialytic therapy and adequate nutrition; aortic
manipulating procedures were usually postponed. To-
gether, these data suggest that an aggressive therapeu-
tic approach with patient-tailored supportive measures
could be associated with a more favorable clinical out-
come.
Address for correspondence:
Francesco Scolari, MD
Scuola di Specializzazione in Nefrologia Clinica,
Università degli Studi di Brescia 
UO Nefrologia, Spedali Civili
Pzle Spedali Civili 1
25100 Brescia - Italy
fscolar@tin.itCholesterol crystal embolism (atheroembolism)
160
REFERENCES
1.  Kassirer J. Atheroembolic renal disease. N Engl J Med
1969; 280: 812-18.
2.  Fine MJ, Kapoor W, Falanga V. Cholesterol crystal em-
bolization: a review of 221 cases in the English literature.
Angiology 1987; 42: 769-84.
3.  Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic
disease. Case report and review of the literature. Am J
Nephrol 1993; 13: 489-93.
4.  Saleem S, Lakkis FG, Martý´nez-Maldonado M. Atheroem-
bolic renal disease. Semin Nephrol 1996; 16: 309-18.
5.  Colt HG, Begg RJ, Saporito J, Cooper WM, Shapiro AP.
Cholesterol emboli after cardiac catheterization. Eight cas-
es and review of the literature. Medicine (Baltimore) 1988;
67: 389-400.
6.  Dahlberg P, Frecentese D, Cogbill T. Cholesterol embolism:
Experience with 22 histologically proven cases. Surgery
1989; 105: 737-46.
7.  Flory CM. Arterial occlusion produced by emboli from erod-
ed aortic atheromatous plaques. Am J Pathol 1945; 21: 549-
65.
8.  Thadani R, Camargo C, Xavier R, Fang L, Bazari H.
Atheroembolic renal failure after invasive procedures. Nat-
ural history based on 52 biopsy-proven cases. Medicine
(Baltimore) 1995; 74: 350-8.
9.  Belenfant X, Meyrier A, Jacquot C. Supportive treatment im-
proves survival in multivisceral cholesterol crystal em-
bolism. Am J Kidney Dis 1999; 33: 840-50.
10.  Scolari F, Bracchi M, Valzorio B, et al. Cholesterol athero-
matous embolism: an increasingly recognized cause of
acute renal failure. Nephrol Dial Transplant 1996; 11:
1607-12.
11.  Mayo RR, Swartz RD. Redefining the incidence of
clinically detectable atheroembolism. Am J Med
1996; 100: 524-9.
12.  Scolari F, Ravani P, Gaggi R, et al. The challenge of diag-
nosing atheroembolic renal disease: clinical features and
prognostic factors. Circulation 2007 (in press).
13.  Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephro-
toxic risks of renal angiography: contrast-media associat-
ed nephrotoxicity and atheroembolism. A critical review.
Am J Kidney Dis 1994; 24: 713-27.
14.  Waters D. Plaque stabilization: a mechanism for the ben-
eficial effect of lipid-lowering therapies in angiographic
studies. Prog Cardiovasc Dis 1994; 37: 107-20.
15.  Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lower-
ing therapy compared with angioplasty in stable coronary
artery disease. N Engl J Med 1999; 341: 70-6.
16.  Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal
embolism: a recognizable cause of renal disease. Am J
Kidney Dis 2000; 36: 1089-109.